02.06.2016 00:05:00

AbbVie Inc. -- Moody's downgrades AbbVie to Baa2; stable outlook

New York, June 01, 2016 -- Moody's Investors Service downgraded the senior unsecured ratings of AbbVie Inc. ("AbbVie") to Baa2 from Baa1. This concludes a rating review for downgrade initiated on April 28, 2016 when AbbVie announced that it would acquire Stemcentrx Inc. for $5.8 billion. At the same time, Moody's affirmed AbbVie's Prime-2 rating on commercial paper obligations. Moody's also converted provisional ratings of (P)Baa2 assigned on May 9, 2016 to definitive ratings of Baa2. Following these actions, the rating outlook is stable.

Vollständigen Artikel bei Moodys lesen